Eli Lilly Price To Sales vs. Return On Asset
| LLY Stock | USD 755.00 6.99 0.93% |
Eli Lilly Price To Sales Ratio |
|
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.62 | 0.7925 |
|
| |||||
| Operating Profit Margin | 0.28 | 0.3026 |
|
| |||||
| Pretax Profit Margin | 0.25 | 0.1921 |
|
|
For Eli Lilly profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Eli Lilly to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Eli Lilly and utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Eli Lilly's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Eli Lilly and over time as well as its relative position and ranking within its peers.
Eli |
Eli Lilly's Revenue Breakdown by Earning Segment
Check out Correlation Analysis.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eli Lilly. If investors know Eli will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eli Lilly listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.682 | Dividend Share 5.03 | Earnings Share 9.28 | Revenue Per Share 45.368 | Quarterly Revenue Growth 0.204 |
The market value of Eli Lilly is measured differently than its book value, which is the value of Eli that is recorded on the company's balance sheet. Investors also form their own opinion of Eli Lilly's value that differs from its market value or its book value, called intrinsic value, which is Eli Lilly's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eli Lilly's market value can be influenced by many factors that don't directly affect Eli Lilly's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eli Lilly's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eli Lilly is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eli Lilly's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Eli Lilly Return On Asset vs. Price To Sales Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Eli Lilly's current stock value. Our valuation model uses many indicators to compare Eli Lilly value to that of its competitors to determine the firm's financial worth. Eli Lilly and is currently regarded as number one stock in price to sales category among its peers. It also is currently regarded as number one stock in return on asset category among its peers reporting about 0.01 of Return On Asset per Price To Sales. The ratio of Price To Sales to Return On Asset for Eli Lilly and is roughly 118.01 . At this time, Eli Lilly's Price To Sales Ratio is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Eli Lilly's earnings, one of the primary drivers of an investment's value.Eli Lilly's Earnings Breakdown by Geography
Eli Return On Asset vs. Price To Sales
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Eli Lilly |
| = | 16.46 X |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Eli Lilly |
| = | 0.14 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Eli Return On Asset Comparison
Eli Lilly is currently under evaluation in return on asset category among its peers.
Eli Lilly Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Eli Lilly, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Eli Lilly will eventually generate negative long term returns. The profitability progress is the general direction of Eli Lilly's change in net profit over the period of time. It can combine multiple indicators of Eli Lilly, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -4.3 B | -4.5 B | |
| Operating Income | 10.3 B | 10.8 B | |
| Income Before Tax | 6.6 B | 3.5 B | |
| Total Other Income Expense Net | -3.8 B | -3.6 B | |
| Net Income | 5.2 B | 3.1 B | |
| Income Tax Expense | 1.3 B | 810.6 M | |
| Net Income Applicable To Common Shares | 7.2 B | 4 B | |
| Net Income From Continuing Ops | 5.2 B | 4.4 B | |
| Non Operating Income Net Other | -288.8 M | -274.4 M | |
| Interest Income | 173.6 M | 204.8 M | |
| Net Interest Income | -312.3 M | -327.9 M | |
| Change To Netincome | -601.6 M | -571.5 M | |
| Net Income Per Share | 5.82 | 6.11 | |
| Income Quality | 0.81 | 0.85 | |
| Net Income Per E B T | 0.80 | 0.60 |
Eli Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Eli Lilly. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Eli Lilly position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Eli Lilly's important profitability drivers and their relationship over time.
Use Eli Lilly in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eli Lilly position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eli Lilly will appreciate offsetting losses from the drop in the long position's value.Eli Lilly Pair Trading
Eli Lilly and Pair Trading Analysis
The ability to find closely correlated positions to Eli Lilly could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eli Lilly when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eli Lilly - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eli Lilly and to buy it.
The correlation of Eli Lilly is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eli Lilly moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eli Lilly moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eli Lilly can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Eli Lilly position
In addition to having Eli Lilly in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Aggressive Defence Thematic Idea Now
Aggressive Defence
Macroaxis small cap, aggressive-outlook picks designed for investors that are willing to accept higher levels of risk to hedge exposure to above-average market volatility. The Aggressive Defence theme has 50 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aggressive Defence Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Eli Stock Analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.